MX2009009171A - Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico. - Google Patents

Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico.

Info

Publication number
MX2009009171A
MX2009009171A MX2009009171A MX2009009171A MX2009009171A MX 2009009171 A MX2009009171 A MX 2009009171A MX 2009009171 A MX2009009171 A MX 2009009171A MX 2009009171 A MX2009009171 A MX 2009009171A MX 2009009171 A MX2009009171 A MX 2009009171A
Authority
MX
Mexico
Prior art keywords
weight loss
metabolic syndrome
administration
treatment
triglyceride levels
Prior art date
Application number
MX2009009171A
Other languages
English (en)
Inventor
Louis R Bucalo
Eugene Morkin
Steven Goldman
Original Assignee
Univ Arizona State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State filed Critical Univ Arizona State
Publication of MX2009009171A publication Critical patent/MX2009009171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona métodos y composiciones para estimular la pérdida de peso o para disminuir los niveles de triglicéridos en un individuo que tenga necesidad de lo mismo; en los métodos de la invención, se administra a un individuo una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de DITPA, y opcionalmente uno o una pluralidad de agentes para disminuir los lípidos, para estimular la pérdida de peso, disminuir los triglicéridos y/o los niveles de lipoproteína y/o para tratar uno o más síntomas del síndrome metabólico.
MX2009009171A 2007-02-27 2008-02-27 Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico. MX2009009171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90399407P 2007-02-27 2007-02-27
PCT/US2008/002680 WO2008106213A1 (en) 2007-02-27 2008-02-27 Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.

Publications (1)

Publication Number Publication Date
MX2009009171A true MX2009009171A (es) 2010-03-04

Family

ID=39721556

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009171A MX2009009171A (es) 2007-02-27 2008-02-27 Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico.

Country Status (5)

Country Link
US (1) US8399518B2 (es)
AU (1) AU2008219585A1 (es)
CA (1) CA2679402A1 (es)
MX (1) MX2009009171A (es)
WO (1) WO2008106213A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012171065A1 (en) * 2011-06-17 2012-12-20 Esra Ogru Treatment of allan-herndon-dudley syndrome with 3,5-diiodothyropropionic acid (ditpa).
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
AU2019275409B2 (en) 2018-05-24 2024-08-15 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2024015764A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC 3,5-diiodothyropropionic acid compositions and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3109023A (en) * 1958-06-10 1963-10-29 Hooker Chemical Corp 2, 3, 6-trichloro-5-nitrobenzoic acid and salts thereof
ZA824382B (en) * 1981-07-07 1984-02-29 Wyeth John & Brother Ltd Anti-obesity agents
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB8801306D0 (en) * 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US20050159490A1 (en) * 2001-01-31 2005-07-21 Eugene Morkin Method to treat chronic heart failure and/or elevated cholesterol levels
US6534676B2 (en) * 2001-01-31 2003-03-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.

Also Published As

Publication number Publication date
AU2008219585A1 (en) 2008-09-04
CA2679402A1 (en) 2008-09-04
WO2008106213A1 (en) 2008-09-04
US8399518B2 (en) 2013-03-19
US20100249235A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
PH12020500332A1 (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2008124505A3 (en) Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
WO2008147482A3 (en) Methods and compositions for improving immune responses
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
WO2006068768A3 (en) Methods and compositions for treating conditions
CO6270215A2 (es) Trans-clomifeno para el sindrome metabolico
IL194883A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
MX2009012109A (es) Composiciones contra el insomnio y metodos.
MX2009009171A (es) Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico.
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
WO2012112677A3 (en) Methods for treating lysosomal acid lipase deficiency
MX342020B (es) Apolipoproteina a-iv como un peptido antidiabetico.
JP2009534367A5 (es)
Lee et al. Lipid emulsions enhance the norepinephrine-mediated reversal of local anesthetic-induced vasodilation at toxic doses
BR112015009504A2 (pt) inibidores de rock
WO2009126805A3 (en) Therapeutic tarageting of mmps in neutral liposomes

Legal Events

Date Code Title Description
FG Grant or registration